ABSTRACT
Objective To investigate the clinical efficacy of combination treatment of Ambroxol,Ipratropium and Budesonide during perioperative period in elderly patients with cardiac adenocarcinoma and chronic obstructive pulmonary disease(COPD).Methods A total of 126 elderly patients aged over 65 years diagnosed as cardiac adenocarcinoma and COPD were selected,and no chemotherapy was given to them before operation.Patients were randomly divided into experimental group(n＝ 62)and control group(n＝ 64).Intravenous infusion of Ambroxol hydrochloride and atomizing inhalation of Ipratropium were given in both groups,and the experimental group received budesonide additionally.The pulmonary function,postoperative pulmonary atelectasis,pulmonary infection,antibiotics application and hospitalization after operation were compared between the two groups.Results The forced expiratory volume at the first second(FEV1),forced vital capacity(FVC)and FEV1/FVC were higher in experimental group than in control group [(1.79 ± 0.52)1 vs.(1.33 ± 0.38)L,(2.44 ±0.43)Lvs.(1.93 ± 0.36)L and(73.91 ± 8.17)％ vs.(62.87 ± 7.23)％,respectively,allP＜0.05].The postoperative pulmonary atelectasis and pulmonary infection were lower in experimental group than in control group(4.8％ vs.15.6％,6.5％ vs.18.8％,respectively,both P＜0.05).The time for antibiotics application after operation had no difference between the two groups[(4.81±1.20) days vs.(5.98 ± 1.17)days,P ＞ 0.05].There was a significant difference in postoperative hospitalization between the two groups [(8.37 ± 0.27) days vs.(11.80 ± 0.33) days,P ＜ 0.05].Conclusions The combination treatment of Ambroxol hydrochloride,Ipratropium and Budesonide during perioperative period achieves better therapeutic effects than does the combination treatment of ambroxol hydrochloride and ipratropium in elderly patients with cardiac adenocarcinoma and COPD.
ABSTRACT
The roles of pharmacists in clinical trials including GCP training , drug administration , evaluation of drug safety issues in clinical trials and regimen design etc were discussed and prospected in the paper .The roles of pharmacists are decisive , and they will play more important roles in clinical trials .
ABSTRACT
This study aims to analyze and improve Howland current source circuit and to study the constant current source of alternating current with high output impedance and high stability. A simulation study was carried out on the constant-current characteristics of Howland current source from two aspects of resistance match value and the selection of Op amp parameters, and then the output impedance was analyzed. The simulation experiment showed that when it was with the best matched resistance, the constant-current characteristics of Howland current source was better. Op amp parameters could affect the constant-current characteristics of Howland current source. In Howland current source circuit, the current source after parameter optimization had better output impedance and load capacity. The results showed that there was the best matched resistance in the selection by Howland current source. The Op amp with large broadband, high slew rate and open loop gain, and wide range of power supply voltage is more suitable for the bioelectrical impedance detection circuit.
Subject(s)
Electric Impedance , Electric Power Supplies , ElectricityABSTRACT
The aim of the study was to investigate the sesquiterpene constituents from the rhizomes of Curcuma wenyujin Y．H．Chen et C．Ling．The isolation and purification of the constituents from the 50％ EtOH extracts of the rhizomes were performed with repeated column chromatography over sillica gel and macroporous resin．Eight sesquiterpenes were obtained and identified as wenyujinlactone A(1),neolitamone A(2),zedoarondiol(3),isozedoarondiol(4),aerugidiol(5),curcumol (6),curdione(7) and (1R,10R)-epoxy-(-)-1,10-dihydrocurdine (8) by means of spectral analysis．Among them,compound 1 was found to be a new eudesmane sesquiterpene lactone,whilst compounds 2-5 were obtained from this plant for the first time．
ABSTRACT
Objective To study the effects of verussurinine (VSRN), an alkaloid isolated from Veratrum nigrum var. ussuriense alkaloids (VnA), against thrombosis and its platelet aggregation inhibitory activity in rats in order to find out whether VSRN is the antithrombotic active ingredient of VnA. Methods The electrically induced rat carotid artery thrombosis and stasis-induced rat inferior vena cava thrombosis models were used to evaluate the anti-arterial and anti-venous thrombosis effect of VSRN, respectively. Borns turbidimetric method was used to examine the in vivo and in vitro anti-platelet effect so as to investigate the antiplatelet aggregation of VSRN. Results In comparison with saline, VSRN in five different doses (1.25—20.00 ?g/kg) showed significantly and dose-dependently prolonged occlusion time (OT) of carotid artery injured by electrical stimulation and reduced thrombus dry weight of inferior vena cava ligated for 4 h to cause stasis. Platelet aggregation was found to be inhibited by VSRN in the doses of 1.25—5.00 ?g/kg and at the concentration of 6.25—50 ?g/L in both in vivo and in vitro test. Conclusion VSRN has powerful arteriovenous antithrombosis and antiplatelet aggregation of rats. The antithrombotic effect of VSRN is related to its platelet aggregation inhibitory activity. The above findings indicate that VSRN is an antithrombotic active ingredient of VnA.
ABSTRACT
Object To study the effects of Veratrum nigrum L. var. ussuriense Nakai alkaloids (VnA) on platelet aggregation in rats and coagulation time, bleeding time in mice. Methods The antiplatelet effect of VnA was examined by determining platelet aggregation rate in normal rats and blood stasis model rats by turbidimetric method developed by Born. Whole blood coagulation time (CT) in mice was measured by capillary glass tube method, bleeding time (BT) by hemorrhagic transection of mouse tail model. Results VnA (45, 30, and 15 ?g/kg, iv) significantly inhibited ADP-induced platelet aggregation in rats in a dose-dependent manner. VnA (12.5, 25, 50, and 100 ?g/kg, ip) markedly increased CT and BT in mice. VnA [49.3 ?g/kg, which was anticoagulantly equieffective to heparin (1.25 mg/kg), ip] prolonged BT. There was no statistically significant difference in BT between VnA and heparin, although BT increase induced by VnA was shorter than that induced by heparin. Conclusion VnA has significant antiplatelet effect in rats and can prolong CT and BT in mice. At equieffective dose VnA-induced BT increase does not exceed that heparin induced.